Immucell (ICCC) Total Non-Current Liabilities (2010 - 2026)

Immucell (ICCC) has reported Total Non-Current Liabilities for 17 consecutive years, with $10.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 12.8% year-over-year to $10.8 million; the trailing twelve-month figure through Jun 2026 stood at $10.8 million (down 12.8% YoY), and the FY2025 full-year result was $11.5 million, down 12.69% from the prior year.
• Total Non-Current Liabilities fell to $10.8 million in Q2 2026 per ICCC's latest filing, from $11.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $15.2 million in Q3 2023 and bottomed at $10.7 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $12.5 million across 5 years, with a median of $12.4 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities gained 29.9% in 2023, then retreated 12.8% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $11.4 million in 2022, then increased by 28.13% to $14.6 million in 2023, then dropped by 9.9% to $13.2 million in 2024, then decreased by 12.69% to $11.5 million in 2025, then retreated by 5.91% to $10.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.8 million, $11.5 million, and $11.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.